Application and Prospects of Molecular Imaging in Immunotherapy.
Application and Prospects of Molecular Imaging in Immunotherapy.
复制标题
DOI：
10.2147/cmar.s269773
复制
发表时间：
2020
影响因子：
3.3
通讯作者：
Meng X
中科院分区：
文献类型：
--
作者：
Wang W;Gao Z;Wang L;Li J;Yu J;Han S;Meng X
最近，靶向程序性细胞死亡1（PD-1）与其主要配体程序性死亡配体1（PD-L1）和程序性死亡配体2（PD-L2）的相互作用的免疫疗法已经取得了显著的成功。迄今为止，已经开发了几种靶向PD-1/PD-L1通路的免疫检查点抑制剂来治疗黑色素瘤、非小细胞肺癌、头颈癌、肾细胞癌和尿路上皮癌。尽管免疫疗法的结果很有希望，但目前用于预测免疫益处的几种免疫生物标志物以及用于评估免疫疗法的疗效和预后以及监测不良反应的传统成像存在许多局限性。本文介绍一种新的成像方法--分子成像。本文从检测PD-1/PD-L1的表达、评价免疫治疗的疗效、评估免疫治疗的预后、监测免疫治疗的毒副反应、其他靶点显像等方面综述了分子影像学在当前免疫治疗中的应用及前景。
Recently, immunotherapies that target the interactions of programmed cell death 1 (PD-1) with its major ligands, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), have achieved significant success. To date, several immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have been developed to treat melanoma, non-small cell lung cancer, head and neck cancer, renal cell carcinoma, and urothelial carcinoma. Despite promising outcomes with immunotherapy, there are many limitations to several current immune biomarkers for predicting immune benefits and to traditional imaging for evaluating the efficacy and prognosis of immunotherapy and monitoring adverse reactions. In this review, we recommend a novel imaging method, molecular imaging. This paper reviews the application and prospects of molecular imaging in the context of current immunotherapies in regard to the following aspects: 1) detecting the expression of PD-1/PD-L1; 2) evaluating the efficacy of immunotherapy; 3) assessing patient prognosis with immunotherapy; 4) monitoring the toxicity of immunotherapy; and 5) other targets imaging.